U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939919) titled 'A Study of AK158D1 in Advanced Solid Tumors' on Nov. 01.

Brief Summary: This is a first-in-human, phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor efficacy of AK158D1 in advanced solid tumors.

Study Start Date: Nov. 16

Study Type: INTERVENTIONAL

Condition: Solid Malignant Tumor

Intervention: DRUG: AK158D1

Subjects will receive AK158D1 via intravenous infusion (IV) in prespecified dose levels.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Akeso

Published by HT Digital Content Services with permission from Health Daily Digest....